Clinical Trial Detail

NCT ID NCT03282396
Title Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

mantle cell lymphoma

Therapies

Ibrutinib

Age Groups: adult senior

No variant requirements are available.